Cargando…

Efficacy of Cangrelor as Bridging Therapy Post PCI

BACKGROUND: Dual antiplatelet therapy (DAPT) remains the cornerstone management for the prevention of acute stent thrombosis after percutaneous intervention (PCI). Situations mandating early interruption of DAPT carry a high risk of ischemic complications. Perioperative bridge therapy using Cangrelo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Khan, Abdul A., Murtaza, Ghulam, Khalid, Muhammad, Finniss, Mathew, Helton, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bentham Science Publishers 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8226151/ https://www.ncbi.nlm.nih.gov/pubmed/32108005 http://dx.doi.org/10.2174/1871529X20666200228114925

Ejemplares similares

Cangrelor bridging strategy for liver damage after mechanical chest compression
por: Cereda, Alberto Francesco, et al.
Publicado: (2019)

Efficacy and Safety of Cangrelor in Women Versus Men During Percutaneous Coronary Intervention: Insights From the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) Trial
por: O’Donoghue, Michelle L., et al.
Publicado: (2016)

PCI-to-PCI bridge architecture specification: Revision 1.1
por: PCI Special Interest Group. Portland, OR, USA
Publicado: (1998)

Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience
por: Rossini, Roberta, et al.
Publicado: (2020)

VHDL design of PCI mezzanines (PMC) for a PCI-SCI bridge
por: Fernández, C, et al.
Publicado: (1995)

Efficacy of a Combined Antiplatelet Therapy Is Not Affected by a Simultaneous Binding of Cangrelor and PSB 0777 to Albumin
por: Wzorek, Joanna, et al.
Publicado: (2021)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry
por: Selvarajah, Abi, et al.
Publicado: (2021)

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
por: Cavender, Matthew A., et al.
Publicado: (2016)

Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry
por: Selvarajah, A., et al.
Publicado: (2021)

Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives
por: De Luca, Leonardo, et al.
Publicado: (2021)

Cangrelor Use in Routine Practice: A Two-Center Experience
por: van der Sangen, Niels M. R., et al.
Publicado: (2021)

Urgent Revascularization of the Left Proximal Circumflex Following Cessation of Cangrelor Within Six Hours of Procedure
por: Huang, Sherri, et al.
Publicado: (2023)

Pre-PCI angina post-PCI ischaemia: tales of ordinary madness
por: Marzilli, Mario, et al.
Publicado: (2019)

The efficacy and safety of cangrelor in single vessel vs multivessel percutaneous coronary intervention: Insights from CHAMPION PHOENIX
por: Yong, Celina M., et al.
Publicado: (2019)

Cangrelor ameliorates CLP-induced pulmonary injury in sepsis by inhibiting GPR17
por: Luo, Qiancheng, et al.
Publicado: (2021)

Cangrelor Induces More Potent Platelet Inhibition without Increasing Bleeding in Resuscitated Patients
por: Prüller, Florian, et al.
Publicado: (2018)

Safety of Low Dose Intravenous Cangrelor in Acute Ischemic Stroke: A Case Series
por: Salahuddin, Hisham, et al.
Publicado: (2021)

The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIX
por: Gutierrez, J. Antonio, et al.
Publicado: (2016)

P2Y(12) Receptor Function and Response to Cangrelor in Neonates With Cyanotic Congenital Heart Disease
por: Kaza, Elisabeth A., et al.
Publicado: (2017)

Cost-Consequence Analysis of Using Cangrelor in High Angiographic Risk Percutaneous Coronary Intervention Patients: A US Hospital Perspective
por: Jensen, Ivar S., et al.
Publicado: (2021)

Left Atrial Tumor Thrombus in a Patient With Squamous Cell Carcinoma of Lung
por: Murtaza, Ghulam, et al.
Publicado: (2019)

Risk Stratification for Transcatheter Aortic Valve Replacement
por: Khan, Abdul Ahad, et al.
Publicado: (2019)

Right Ventricle Perforation Post Pacemaker Insertion Complicated with Cardiac Tamponade
por: Khalid, Muhammad, et al.
Publicado: (2018)

Advanced pharmacodynamics of cangrelor in healthy volunteers: a dose-finding, open-label, pilot trial
por: Gelbenegger, Georg, et al.
Publicado: (2022)

Application of Edge Computing in Structural Health Monitoring of Simply Supported PCI Girder Bridges
por: Lin, Yi-Ching, et al.
Publicado: (2022)

Real-World Experience with Cangrelor as Adjuvant to Percutaneous Coronary Intervention: A Single-Centre Observational Study
por: Thim, Troels, et al.
Publicado: (2023)

Pre-PCI versus immediate post-PCI Impella initiation in acute myocardial infarction complicated by cardiogenic shock
por: Hemradj, Veemal V., et al.
Publicado: (2020)

Intravenous antiplatelet therapies (glycoprotein IIb/IIIa receptor inhibitors and cangrelor) in percutaneous coronary intervention: from pharmacology to indications for clinical use
por: Capodanno, Davide, et al.
Publicado: (2019)

Adenosine Receptor Agonist HE-NECA Enhances Antithrombotic Activities of Cangrelor and Prasugrel in vivo by Decreasing of Fibrinogen Density in Thrombus
por: Polak, Dawid, et al.
Publicado: (2021)

The future of angiography: Estimates of FFR pre‐ and post‐PCI
por: Tehrani, David M., et al.
Publicado: (2022)

Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIX
por: Cavender, Matthew A., et al.
Publicado: (2021)

Drug-Coated Balloon Treatment for ACS Induced by Myocardial Bridging: An Intravascular Ultrasound-Guided PCI
por: Shen, Linghong, et al.
Publicado: (2020)

The use of cangrelor with heparin for left ventricular assist device implantation in a patient with acute heparin-induced thrombocytopenia
por: Gernhofer, Yan K., et al.
Publicado: (2018)

Predictors of subjective health status 10 years post-PCI
por: van den Berge, Jan C., et al.
Publicado: (2016)

Valvular Hemolysis Masquerading as Prosthetic Valve Stenosis
por: Sethi, Pooja, et al.
Publicado: (2017)

Safety and Efficacy Evaluation of Antithrombotic Therapy with Rivaroxaban and Clopidogrel After PCI in Chinese Patients
por: Bai, Long, et al.
Publicado: (2022)

Analysis of the Financial Impact of Using Cangrelor on the Safety and Efficacy Outcomes in Patients Undergoing Percutaneous Coronary Intervention in Whom Oral Therapy with P2Y(12) Inhibitors is Not Feasible or Desirable, in Spain
por: Lizano-Díez, Irene, et al.
Publicado: (2021)

Safety and Efficacy of Cangrelor Among Three Antiplatelet Regimens During Stent-Assisted Endovascular Treatment of Unruptured Intracranial Aneurysm: A Single-Center Retrospective Study
por: Cheddad El Aouni, Mourad, et al.
Publicado: (2022)

Haemophilus parainfluenzae Pyogenic Liver Abscess Associated With Cholangiocarcinoma
por: Finniss, Mathew C, et al.
Publicado: (2022)

Variation in Patient Profiles and Outcomes in US and Non-US Subgroups of the Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION) PHOENIX Trial
por: Vaduganathan, Muthiah, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_h75jk8mad91125prb8n61ji6ka